Search Results

You are looking at 51 - 60 of 106 items for :

  • "Bladder cancer" x
  • All content x
Clear All
Full access

Richard T. Hoppe

approve IMRT for “prostate, head and neck, thyroid, central nervous system, and pediatric tumors; anal, rectal, and bladder cancers; gynecologic tumors; pelvic sarcomas; certain left breast and lung cancers.” But for mediastinal lymphoma, IMRT was

Full access

Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde, and Mike G. Martin

Hollenbeak CS . Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005 . BJU Int 2011 ; 107 : 1059 – 1064 . 2. Gallagher DJ Milowsky MI Bajorin DF . Advanced bladder cancer: status of first

Full access

Donald A. Podoloff, Douglas W. Ball, Edgar Ben-Josef, Al B. Benson III, Steven J. Cohen, R. Edward Coleman, Dominique Delbeke, Maria Ho, David H. Ilson, Gregory P. Kalemkerian, Richard J. Lee, Jay S. Loeffler, Homer A. Macapinlac, Robert J. Morgan Jr., Barry Alan Siegel, Seema Singhal, Douglas S. Tyler, and Richard J. Wong

bone metastases . Anticancer Res 2000 ; 20 : 2189 – 2192 . 75 Picchio M Treiber U Beer AJ . Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings . J Nucl Med 2006

Full access

, especially in high-risk patients. AB2014-10. Table 1: Comparison of Risk Categorization Bladder Cancer AB2014-11. Chronic Kidney Disease Epidemiology and Cockcroft-Gault Equations Identify Similar Candidates for Neoadjuvant Chemotherapy in

Full access

Chandrakanth Are

obstruction in gall bladder cancer is not sine qua non of inoperability . Ann Surg Oncol 2007 ; 14 : 2831 – 2837 .

Full access

Anthony J. Olszanski

bacillus Calmette–Guérin vaccine for bladder cancer in 1976 and the first monoclonal antibody (muromonab) in 1986. He also noted the first monoclonal antibody in cancer (rituximab) in 1997, “which changed the face of treatment for a number of patients with

Full access

for the following NCCN Guidelines are available: Acute Lymphoblastic Leukemia, Version 1.2016 Acute Myeloid Leukemia, Version 1.2016 Bladder Cancer, Version 2.2016 Breast Cancer, Version 2.2016 Genetic/Familial High-Risk Assessment: Breast

Full access

resources in parts of Africa. So far, the NCCN Harmonized Guidelines for Sub-Saharan Africa include: Adult Cancer Pain Antiemesis (nausea and vomiting prevention) B-Cell Lymphomas (Non-Hodgkin’s Lymphomas) Bladder Cancer Breast Cancer Cervical Cancer Chronic

Full access

James Perkins, Patrick Boland, Steven J. Cohen, Anthony J. Olszanski, Yan Zhou, Paul Engstrom, and Igor Astsaturov

bladder cancer has been documented, but this strategy is not considered to be a standard treatment option. 13 The mechanism through which KIF11 inhibition produced such a dramatic response in the present patient, whose tumor was refractory to chemotherapy

Full access

Kelsey C. Stoltzfus, Biyi Shen, Leila Tchelebi, Daniel M. Trifiletti, Niraj J. Gusani, Vonn Walter, Ming Wang, and Nicholas G. Zaorsky

addition, a study of patients with muscle-invasive bladder cancer found no difference in survival between patients treated at a high-volume versus low-volume facility (HR, 0.99; 95% CI, 0.94–1.04). 9 Mixed findings across different cancer sites may be